226 related articles for article (PubMed ID: 37124623)
61. A cuproptosis-related LncRNA signature: Integrated analysis associated with biochemical recurrence and immune landscape in prostate cancer.
Ren L; Yang X; Wang W; Lin H; Huang G; Liu Z; Pan J; Mao X
Front Genet; 2023; 14():1096783. PubMed ID: 36911392
[No Abstract] [Full Text] [Related]
62. A prognostic signature of cuproptosis and TCA-related genes for hepatocellular carcinoma.
Zhang Q; Ma L; Zhou H; Zhou Y; Liu S; Li Q
Front Oncol; 2022; 12():1040736. PubMed ID: 36324575
[TBL] [Abstract][Full Text] [Related]
63. Potential Role of Cuproptosis-Related Lncrna in Prognosis and Immunotherapy of Thyroid Carcinoma.
Cai Y; Niu B; Gao J; Su H
Iran J Public Health; 2023 May; 52(5):995-1007. PubMed ID: 37484723
[TBL] [Abstract][Full Text] [Related]
64. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
Bai Y; Zhang Q; Liu F; Quan J
Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
[TBL] [Abstract][Full Text] [Related]
65. Development and validation of cuproptosis-related lncRNA signatures for prognosis prediction in colorectal cancer.
Pang L; Wang Q; Wang L; Hu Z; Yang C; Li Y; Wang Z; Li Y
BMC Med Genomics; 2023 Mar; 16(1):58. PubMed ID: 36949429
[TBL] [Abstract][Full Text] [Related]
66. Cuproptosis-related lncRNA signature for prognostic prediction in patients with acute myeloid leukemia.
Zhu Y; He J; Li Z; Yang W
BMC Bioinformatics; 2023 Feb; 24(1):37. PubMed ID: 36737692
[TBL] [Abstract][Full Text] [Related]
67. Identification and validation of a novel cuproptosis-related lncRNA signature for prognosis and immunotherapy of head and neck squamous cell carcinoma.
Xu QS; Shen ZZ; Yuan LQ
Front Cell Dev Biol; 2022; 10():968590. PubMed ID: 36467424
[TBL] [Abstract][Full Text] [Related]
68. A comprehensive analysis focusing on cuproptosis to investigate its clinical and biological relevance in uterine corpus endometrial carcinoma and its potential in indicating prognosis.
Wu Q; Tian R; Tan H; Liu J; Ou C; Li Y; Fu X
Front Mol Biosci; 2022; 9():1048356. PubMed ID: 36567939
[TBL] [Abstract][Full Text] [Related]
69. Developing four cuproptosis-related lncRNAs signature to predict prognosis and immune activity in ovarian cancer.
Liu L; Wang Q; Zhou JY; Zhang B
J Ovarian Res; 2023 Apr; 16(1):88. PubMed ID: 37122030
[TBL] [Abstract][Full Text] [Related]
70. Characterization of cuproptosis-related lncRNA landscape for predicting the prognosis and aiding immunotherapy in lung adenocarcinoma patients.
Sun X; Song J; Lu C; Sun X; Yue H; Bao H; Wang S; Zhong X
Am J Cancer Res; 2023; 13(3):778-801. PubMed ID: 37034212
[TBL] [Abstract][Full Text] [Related]
71. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for low grade glioma.
Wen J; Zhao W; Shu X
Front Oncol; 2022; 12():1087762. PubMed ID: 36776374
[TBL] [Abstract][Full Text] [Related]
72. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
Front Immunol; 2022; 13():919231. PubMed ID: 35967366
[TBL] [Abstract][Full Text] [Related]
73. Identification of cuproptosis-related lncRNAs to predict prognosis and immune infiltration characteristics in alimentary tract malignancies.
Xie Y; Song X; Du D; Ni Z; Huang H
BMC Bioinformatics; 2023 May; 24(1):184. PubMed ID: 37142949
[TBL] [Abstract][Full Text] [Related]
74. A combination of cuproptosis and lncRNAs predicts the prognosis and tumor immune microenvironment in cervical cancer.
Huang Y; Pan C; Wu S; Ye F; Yang L
Discov Oncol; 2024 Apr; 15(1):116. PubMed ID: 38609663
[TBL] [Abstract][Full Text] [Related]
75. Cuproptosis-related gene signatures for predicting prognosis of lung adenocarcinoma.
Ye W; Huang Y; Li X
Medicine (Baltimore); 2022 Oct; 101(40):e30446. PubMed ID: 36221373
[TBL] [Abstract][Full Text] [Related]
76. Identification of cuproptosis-associated IncRNAs signature and establishment of a novel nomogram for prognosis of stomach adenocarcinoma.
Yu W; Huo H; You Z; Lu R; Yao T; Huang J
Front Genet; 2022; 13():982888. PubMed ID: 36160008
[No Abstract] [Full Text] [Related]
77. Cuproptosis-related LncRNA signatures as a prognostic model for head and neck squamous cell carcinoma.
Sun Q; Qin X; Zhao J; Gao T; Xu Y; Chen G; Bai G; Guo Z; Liu J
Apoptosis; 2023 Feb; 28(1-2):247-262. PubMed ID: 36344660
[TBL] [Abstract][Full Text] [Related]
78. Comprehensive analysis of cuproptosis-related long noncoding RNA immune infiltration and prediction of prognosis in patients with bladder cancer.
Zhang Y; Li X; Li X; Zhao Y; Zhou T; Jiang X; Wen Y; Meng W; Li S
Front Genet; 2022; 13():990326. PubMed ID: 36186475
[No Abstract] [Full Text] [Related]
79. The Cuproptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Immune Cell Infiltration in Hepatocellular Carcinoma.
Li Y; Song K; Zheng W
J Oncol; 2023; 2023():9557690. PubMed ID: 36891559
[TBL] [Abstract][Full Text] [Related]
80. Cuproptosis Combined with lncRNAs Predicts the Prognosis and Immune Microenvironment of Breast Cancer.
Zhang L; Zhang Y; Bao J; Gao W; Wang D; Pan H
Comput Math Methods Med; 2022; 2022():5422698. PubMed ID: 36213577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
